WHO Sounds Alert Over Acute Lack of Obesity Medications
Under a tenth of patients eligible to benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it issues its inaugural guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that obesity is a chronic disease that can be managed with thorough and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant obstacles to broad access to the jabs that can help people shift substantial weight, says the agency.
Weight-Loss Drug Scarcity
Despite the current most optimistic scenario, the manufacturing of such drugs could only cover around 100 million people – less than 10% of the global need, per the WHO.
The guideline calls on governments and firms to expand availability, through approaches like voluntary licensing.
The intellectual property rights on semaglutide – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so users eat less.
People commonly start to lose weight after several weeks of commencing the weekly injections.
Evidence indicates people may regain a significant portion a year later of discontinuing the treatment, as their usual appetite come back.
Being carrying excess weight raises your chance for developing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
